Dr Reddy's launches Raloxifene tablets in the US

Dr. Reddy's Laboratories announces the launch of Raloxifene HCl Tablets, USP in the U.S. Market

id-10039602-1

Dr. Reddy's Laboratories has announced that it has launched Raloxifene hydrochloride tablets in 60 mg, a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets in the United States market, approved by the U.S. Food & Drug Administration (USFDA).

The Evista brand and generic had U.S. sales of approximately $265 million MAT for the most recent twelve months ending in September 2016 according to IMS Health.

Dr. Reddy's Raloxifene tablets are available in 60 mg in bottle count sizes of 30, 100 and 1,000.


Evista is a registered trademark of Eli Lilly and Company.

 

1 Comment Comment 1 - 1 of 1
comment

fggfg 15 November 2016 at 11:20 AM

good one!

Reply

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email

X